cannabis indica

Demência

termo de indexação original: Dementia

O acervo do Cannabis Indica reúne 69 estudos científicos que tocam a condição Demência, publicados entre 1890 e 2024. Pela leitura automatizada, 59 (86%) foram classificados como favoráveis, 8 (12%) como inconclusivos e 2 (3%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (28 estudos), seguido de estudo em animais (18). Os compostos mais presentes são THC Farmacêutico, Endocanabinoide (não especificado) e 2-Araquidonoilglicerol (2-AG). Aparece com frequência ao lado de Doença de Alzheimer, Disfunção Cognitiva e Doenças Neurodegenerativas.

Estudos indexados
69
Período coberto
1890–2024
Favoráveis
59 · 86%
Inconclusivos
8 · 12%
Desfavoráveis
2 · 3%
Termo original
Dementia

O acervo em números

Tipo de estudo

Metanálise28
Estudo em Animais18
Ensaio Clínico Duplo-Cego8
Metanálise Clínica7
Estudo Laboratorial4
Ensaio Clínico4

Direção do resultado

Favorável59
Inconclusivo8
Desfavorável2

Por década

1890s1
2000s3
2010s14
2020s51

69 estudos

Filtrar e buscar no acervo →
  1. 2024

    Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging

  2. 2024

    Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial

  3. 2024

    Δ9-Tetrahydrocannabinol (THC): A Critical Overview of Recent Clinical Trials and Suggested Guidelines for Future Research

  4. 2023

    Cannabis-Induced Acute Encephalopathy in a 94-Year-Old Woman Due to Family Administration of Cannabidiol (CBD) Products: A Case Report

  5. 2023

    Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial

    FavorávelEnsaio Clínico Duplo-CegoDoença de AlzheimerQualidade de Vida
  6. 2023

    Multi-Targeting Intranasal Nanoformulation as a Therapeutic for Alzheimer's Disease

  7. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  8. 2023

    Synergetic effect of β-asarone and cannabidiol against Aβ aggregation in vitro and in vivo

  9. 2022

    Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer’s Disease Rat Model: A Proof-of-Concept Study

    FavorávelEstudo em AnimaisInflamaçãoDoenças NeurodegenerativasDoença de Alzheimer+1
  10. 2022

    Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  11. 2022

    Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review

  12. 2022

    Cannabis in Palliative Care: A Systematic Review of Current Evidence

    InconclusivoMetanáliseCâncerEpilepsiaInsônia e Distúrbios do Sono+6
  13. 2022

    Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents

  14. 2022

    Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

  15. 2022

    Enhancing endocannabinoid signalling in astrocytes promotes recovery from traumatic brain injury

  16. 2022

    Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  17. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  18. 2022

    Impact of the cannabinoid system in Alzheimer's diseases

  19. 2022

    Improved cognition impairment by activating cannabinoid receptor type 2: Modulating CREB/BDNF expression and impeding TLR-4/NFκBp65/M1 microglia signaling pathway in D-galactose-injected ovariectomized rats

  20. 2022

    Long-term Cannabis Users Show Lower Cognitive Reserves and Smaller Hippocampal Volume in Midlife

  21. 2022

    LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoAnsiedadeAyahuasca+6
  22. 2022

    Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

  23. 2022

    Medical Cannabis and Psychiatric Disorders: Implications for Psychiatric Nurses

    InconclusivoMetanáliseAnsiedadeDoença de AlzheimerTEPT+2
  24. 2022

    Medicinal Herbs in the Relief of Neurological, Cardiovascular, and Respiratory Symptoms after COVID-19 Infection A Literature Review

  25. 2022

    Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção Cognitiva+4
  26. 2022

    Neuroprotective effect of alpha-pinene is mediated by suppression of the TNF-α/NF-κB pathway in Alzheimer's disease rat model

    FavorávelEstudo em AnimaisInflamaçãoAnsiedadeDisfunção CognitivaMedicina Mente-Corpo+4
  27. 2022

    Parkinson’s Disease and Dementia with Lewy Bodies, Patients Under Treatment with Standardized Extracts Enriched in Cannabidiol and Cannabigerol: Descriptive Observations in Preparation for a Phase 2a Clinical Trial

    FavorávelMetanáliseDorAnsiedadePsicoseTetraidrocanabinol (THC)Canabigerol (CBG)+3
  28. 2022

    The Effect of Cannabidiol Coated by Nano-Chitosan on Learning and Memory, Hippocampal CB1 and CB2 Levels, and Amyloid Plaques in an Alzheimer's Disease Rat Model

    FavorávelEstudo em AnimaisDoenças NeurodegenerativasDoença de Alzheimer
  29. 2022

    The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials

    FavorávelMetanálise ClínicaDorCâncerEfeitos Adversos da CannabisTHC Farmacêutico+7
  30. 2022

    Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

    FavorávelMetanálise ClínicaDorInflamaçãoDisfunção CognitivaPalmitoiletanolamida (PEA)+8
  31. 2021

    Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer's disease induced by Aβ 1-42 through inhibiting RhoA/ROCK2 pathway

  32. 2021

    Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease

    FavorávelEstudo em AnimaisDisfunção CognitivaDoença de Alzheimer
  33. 2021

    Cannabinoids for Agitation in Alzheimer's Disease

    FavorávelMetanáliseDoença de Alzheimer
  34. 2021

    Cannabinoids for the treatment of dementia

  35. 2021

    Cannabinoids in the management of frontotemporal dementia: a case series

    FavorávelMetanáliseDoença de AlzheimerTOC
  36. 2021

    Cannabis Use among Persons with Dementia and Their Caregivers: Lighting up an Emerging Issue for Clinical Gerontologists

    FavorávelMetanáliseDoença de Alzheimer
  37. 2021

    Lavender and coriander essential oils and their main component linalool exert a protective effect against amyloid-β neurotoxicity

    FavorávelEstudo LaboratorialDoença de AlzheimerMedicina Mente-Corpo
  38. 2021

    Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review

  39. 2021

    Prospects for the Use of Cannabinoids in Psychiatric Disorders

    InconclusivoMetanáliseAnsiedadeDepressãoInsônia e Distúrbios do Sono
  40. 2020

    A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia

    InconclusivoMetanálise ClínicaDoença de Alzheimer
  41. 2020

    Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Aβ-induced neuronal toxicity

    FavorávelEstudo em AnimaisDoença de AlzheimerCanabinoides Sintéticos JWH-x
  42. 2020

    Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis

    FavorávelMetanáliseDisfunção Cognitiva
  43. 2020

    Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ40 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice

    FavorávelEstudo em AnimaisInflamaçãoDisfunção CognitivaDoenças Neurodegenerativas+1
  44. 2020

    Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia

    FavorávelEnsaio ClínicoPalmitoiletanolamida (PEA)
  45. 2020

    Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  46. 2020

    Isomeric O-methyl cannabidiolquinones with dual BACH1/NRF2 activity

    FavorávelEstudo LaboratorialInflamaçãoEstresse OxidativoDoenças Neurodegenerativas+3
  47. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  48. 2020

    Targeting Cannabinoid Receptor Activation and BACE-1 Activity Counteracts TgAPP Mice Memory Impairment and Alzheimer's Disease Lymphoblast Alterations

  49. 2020

    The Cannabinoid Receptor Agonist WIN55,212-2 Ameliorates Hippocampal Neuronal Damage After Chronic Cerebral Hypoperfusion Possibly Through Inhibiting Oxidative Stress and ASK1-p38 Signaling

  50. 2020

    The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study

    FavorávelEnsaio Clínico Duplo-CegoDependência — CannabisAnsiedadePsicoseCanabinoide Sintético (não especificado)+5
  51. 2020

    Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial

    FavorávelEnsaio Clínico Duplo-Cego
  52. 2019

    24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone

  53. 2019

    A Review on Studies of Marijuana for Alzheimer's Disease - Focusing on CBD, THC

  54. 2019

    Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

  55. 2019

    Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines

  56. 2019

    Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview

    FavorávelMetanáliseDisfunção Cognitiva
  57. 2019

    Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva

  58. 2019

    Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia

  59. 2018

    Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2.

  60. 2016

    Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model

    FavorávelEstudo em AnimaisDoença de Alzheimer
  61. 2016

    Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial

    FavorávelEnsaio Clínico Duplo-CegoCondições Geriátricas
  62. 2016

    Safety And Efficacy Of Medical Cannabis Oil For Behavioral And Psychological Symptoms Of Dementia: An-Open Label, Add-On, Pilot Study

    FavorávelMetanáliseDisfunção CognitivaDoença de Alzheimer
  63. 2015

    Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia

  64. 2015

    Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDisfunção CognitivaTHC Farmacêutico+3
  65. 2015

    Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoDoença de AlzheimerTranstornos de ComportamentoTetraidrocanabinol (THC)
  66. 2009

    Cannabinoids for the treatment of dementia

    InconclusivoMetanálise ClínicaDoenças Neurodegenerativas
  67. 2009

    The Activation Of Cannabinoid CB2 Receptors Stimulates In Situ And In Vitro Beta-amyloid Removal By Human Macrophages

    FavorávelEstudo LaboratorialDoença de AlzheimerCanabinoides Sintéticos JWH-x
  68. 2006

    Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.

  69. 1890

    Cannabis Indica

    FavorávelMetanáliseDorDor — CrônicaInsônia e Distúrbios do Sono+6

Continue por aqui

Perguntas frequentes

Quantos estudos sobre demência estão indexados no acervo?
São 69 estudos, publicados entre 1890 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 28 · Estudo em Animais: 18 · Ensaio Clínico Duplo-Cego: 8 · Metanálise Clínica: 7 · Estudo Laboratorial: 4 · Ensaio Clínico: 4. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 59 favoráveis, 8 inconclusivos e 2 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Demência — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/demencia/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Demência — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/demencia/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.